VRX Bausch Health Cos

Item 1.01. Entry into a Material Definitive Agreement.

Credit Agreement Amendment

On March 28, 2017, Valeant Pharmaceuticals International, Inc. (the “Company”) completed an amendment to its Third Amended and Restated Credit and Guaranty Agreement, dated as of February 13, 2012 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Credit Agreement”, and such amendment, the “Revolver Extension amendment”).

The Revolver Extension amendment provides for the extension of the maturity date of $1,190 million of revolving credit commitments under the Credit Agreement from April 20, 2018 to the earlier of (i) April 20, 2020 and (ii) the date that is 91 calendar days prior to the scheduled maturity of any series or tranche of term loans under the Credit Agreement, certain secured or unsecured notes and any other Indebtedness for borrowed money in excess of $750 million (the “2020 series”). Unless otherwise terminated prior thereto, the remaining $310 million of revolving credit commitments under the Credit Agreement will continue to mature on April 20, 2018.

The Company paid fees to each revolving lender with revolving commitments comprising the 2020 series in an amount equal to 0.125% of the aggregate principal amount of such revolving lender’s allocation of the 2020 series.

The foregoing summary of the Revolver Extension amendment is not complete and is qualified in its entirety by reference to the full and complete text of the Revolver Extension amendment, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K, which is incorporated herein by reference.